Herein we presented the pre-clinical utility of the novel, CDK9-selective inhibitor, VIP152 in CLL using well established assays in primary human CLL samples and a mouse model of this disease. This evidence concerns the gene CDK9 and B-cell chronic lymphocytic leukemia.